Key Highlights

● JPMorgan initiated coverage of AbCellera with an Overweight rating and a $17 price target on Tuesday, September 29, 2026.

● The stock was listed among premarket gainers, and a closing move for the regular session was not reported.

● The initiation focused on AbCellera's progress toward becoming a clinical-stage company developing its own medicines.

● Health care was mixed, with uniQure collapsing, Summit Therapeutics soaring and Iovance rocketing on the same day.

AbCellera Biologics Inc. (NASDAQ:ABCL) rose early on Tuesday, September 29, 2026, after JPMorgan initiated coverage of the antibody specialist with an Overweight rating and a $17 price target. The stock was listed among the premarket gainers. A closing move for the regular session was not reported.

JPMorgan's Call

An Overweight rating signals that JPMorgan expects the stock to perform better than the average stock in its coverage universe, and the $17 target gives investors a sense of the value the bank sees. The initiation focused on AbCellera's progress toward becoming a clinical-stage company. Companies that develop their own drugs keep more of the potential upside if those drugs succeed, but they also take on more cost and risk than companies that only provide services. A new initiation from a bank of JPMorgan's size can also broaden a stock's audience among institutional investors.

What AbCellera Does

AbCellera, based in Vancouver, built its Business on a technology platform that searches the immune system for antibodies that could become medicines. For years it earned money mainly by partnering with pharmaceutical companies, receiving research fees and potential milestone payments and royalties. It rose to prominence during the pandemic, when antibodies it discovered were developed into COVID-19 treatments, and it has since been building its own pipeline with the aim of entering human trials.

Biotech in a Tough Tape

Health care was among the declining sectors at midday. uniQure collapsed after four-year Huntington's disease data missed statistical significance, while Summit Therapeutics soared on a $2 billion Equity Investment from AstraZeneca and Iovance rocketed after raising its Revenue guidance.

Rates and Development-Stage Biotech

The 30-year Treasury Yield reached its highest level since 2002, and the 10-year touched its highest in roughly two decades. Higher rates tend to weigh on development-stage biotech companies, because their value depends on profits expected many years ahead and they often need to raise fresh money. The Russell 2000 finished lower, with closing figures from different sources clustered between roughly 2,807 and 2,810.

The Data Backdrop

The S&P 500 closed at 7,670.84, down 12.85 points, and the Dow Jones Industrial Average closed at 51,349.92, down 131.59 points. The Nasdaq Composite ended little changed at 26,797.54. Consumer confidence dropped to 81.9 from 88.6, the lowest since 2014, according to the Conference Board. New York Fed President John Williams said there is no need for urgency after the central bank's September meeting, and odds of an October rate hike fell to roughly a coin flip.